Syndax Pharmaceuticals
Syndax Pharmaceuticals' revenue rose 627.8% to $172 million in fiscal 2025. Its operating margin was −158.4%, up from −1,434.4% a year earlier. Free cash flow was −$323 million. The diluted share count rose 1.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Syndax Pharmaceuticals does
Syndax is a drug company that sells two cancer medicines and is testing more uses for them. Revuforj (revumenib) treats certain relapsed or hard-to-treat acute leukemias, in people with a KMT2A gene change or with an NPM1 gene mutation. Niktimvo (axatilimab-csfr) treats chronic graft-versus-host disease, a condition in which donor cells attack a transplant patient's body, after other treatments have failed. The U.S. Food and Drug Administration approved Niktimvo in August 2024, Revuforj in November 2024, and a second use for Revuforj in October 2025.
Syndax earns money by selling Revuforj itself in the United States. It runs the sales and further development of Revuforj, and works with its partner Incyte on Niktimvo. It licensed the worldwide rights to both medicines from other companies. It describes both as the first of their kind.
The company is also running trials of revumenib with standard treatments in newly diagnosed patients, studying it in a bone marrow disease called myelofibrosis, and testing axatilimab in a lung disease. It plans to license or buy more drug candidates and says it may sell Revuforj outside the United States, alone or with partners.
Its biggest risks, as it describes them
- It relies on two approved medicines, so weak sales or safety problems with either would hurt it.
- Its trials of new uses for its medicines may fail or be delayed, and regulators may not approve them.
- It depends on its partner Incyte for Niktimvo and on licenses from other companies for its medicines.
- Competing medicines, including other drugs aimed at the same target, could take away patients.
- It may need to raise more money, and it depends on outside makers and suppliers.
Income statement
Syndax Pharmaceuticals lost money in fiscal 2025: a net loss of $285 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 440 | 476 | 571 | 573 | 394 |
| Debt incl. finance leases | — | — | 0 | 669 | — |
| Net debt (negative means net cash) | — | — | −571 | 96 | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | 0.0x | 2.3x | — |
| Interest coverage | 13.8x | −48.4x | −1,105.5x | −339,672.0x | −45,514.0x |
| Current ratio | 21.7x | 16.9x | 10.0x | 5.8x | 4.4x |
| Quick ratio | 21.7x | 16.9x | 10.0x | 5.8x | 4.1x |
Cash flow
Projections
Project Syndax Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Syndax Pharmaceuticals shares on the open market, and 3 insiders sold $2.7 million, $2.0 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 8, 2026 | Michael A MetzgerChief Executive Officer, Director | Sold plan | 32,375 | $24.24 | $784,770 | Form 4 |
| Jun 12, 2026 | Nicholas A.J. BotwoodHead of R&D, CMO | Sold plan | 31,235 | $18.14 | $566,603 | Form 4 |
| Jun 11, 2026 | Nicholas A.J. BotwoodHead of R&D, CMO | Sold plan | 34,280 | $18.00 | $617,040 | Form 4 |
| Jun 1, 2026 | Michael A MetzgerChief Executive Officer, Director | Sold | 6,847 | $18.99 | $130,025 | Form 4 |
| Jun 1, 2026 | Keith A. GoldanChief Financial Officer | Sold | 1,177 | $18.99 | $22,351 | Form 4 |
| Feb 9, 2026 | Michael A MetzgerChief Executive Officer, Director | Sold | 17,159 | $21.03 | $360,854 | Form 4 |
| Feb 9, 2026 | Keith A. GoldanChief Financial Officer | Sold | 3,410 | $21.03 | $71,712 | Form 4 |
| Feb 6, 2026 | Michael A MetzgerChief Executive Officer, Director | Sold | 7,412 | $20.62 | $152,835 | Form 4 |
| Feb 6, 2026 | Keith A. GoldanChief Financial Officer | Sold | 2,082 | $20.62 | $42,931 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | 2 of 8 | — |
| Rule of 40 | — | — | 440.3% |
| Altman Z'' | 8.19 | −3.43 | −7.54 |
| Accruals ratio | −8.8% | −6.6% | 6.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | — | Fail | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | 2 of 8 | — |
Compare
Put Syndax Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals | FY25 | 627.8% | −158.4% | −187.5% | — | — | — | |
| Stoke Therapeutics | FY25 | 404.5% | −11.2% | 24.4% | — | — | — | Compare |
| Liquidia | FY25 | 1,031.2% | −32.5% | −25.3% | — | — | — | Compare |
| Rhythm Pharmaceuticals | FY25 | 45.8% | −101.2% | −61.5% | — | — | 6 | Compare |
| IDEAYA Biosciences | FY25 | 3,024.4% | −72.8% | −33.6% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 1 | 2 | 2 | 2 | 2 | 140 | 0 | 0 | 24 | 172 |
| Revenue growth | 94.6% | 72.8% | −28.0% | 0.0% | 0.0% | 9,109.6% | −100.0% | — | — | 627.8% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 32 | 48 | 60 | 43 | 50 | 88 | 118 | 163 | 242 | 259 |
| Operating income | −44 | −62 | −76 | −58 | −71 | 26 | −152 | −230 | −340 | −273 |
| Net income | −44 | −61 | −74 | −56 | −73 | 25 | −149 | −209 | −319 | −285 |
| Diluted EPS (US$) | −3.22 | −2.90 | −2.92 | −1.84 | −1.87 | 0.46 | −2.46 | −2.98 | −3.72 | −3.29 |
| Diluted shares (millions) | 15 | 21 | 25 | 30 | 41 | 54 | 61 | 70 | 86 | 87 |
| Cash flow | ||||||||||
| Cash from operations | −35 | −47 | −68 | −51 | −71 | 29 | −134 | −161 | −275 | −323 |
| Capital expenditure | 0 | 0 | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −35 | −47 | −69 | — | −71 | 29 | −134 | −161 | −275 | −323 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 5 | 6 | 6 | 6 | 9 | 13 | 16 | 31 | 43 | 48 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 105 | 130 | 81 | 60 | 293 | 440 | 476 | 571 | 573 | 394 |
| Debt incl. finance leases | — | — | — | — | — | — | — | 0 | 669 | — |
| Total assets | 109 | 137 | 84 | 64 | 301 | 450 | 497 | 613 | 725 | 530 |
| Total liabilities | 25 | 33 | 31 | 32 | 48 | 41 | 30 | 59 | 437 | 465 |
| Shareholders' equity | 84 | 104 | 53 | 32 | 252 | 408 | 467 | 554 | 288 | 65 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −3,587.4% | −2,939.0% | −5,001.7% | −3,792.9% | −4,708.2% | 18.8% | — | — | −1,434.4% | −158.4% |
| Net margin | −3,645.2% | −2,884.3% | −4,875.5% | −3,694.6% | −4,822.5% | 17.8% | — | — | −1,346.1% | −165.6% |
| Free cash flow margin | −2,903.1% | −2,251.2% | −4,529.9% | — | −4,697.4% | 20.8% | — | — | −1,160.9% | −187.5% |
| Rule of 40 (growth + FCF margin) | −2,808.5% | −2,178.4% | −4,557.9% | — | −4,697.4% | 9,130.3% | — | — | — | 440.3% |
| Return on capital | — | — | — | — | — | — | — | — | −145.8% | — |
| Return on equity | — | −64.5% | −94.0% | −132.4% | −51.6% | 7.5% | −34.1% | −41.0% | −75.7% | −161.8% |
| Return on assets | −44.7% | −49.4% | −66.9% | −76.0% | −40.2% | 6.6% | −31.5% | −37.7% | −47.7% | −45.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |